Nature Clinical Practice Cardiovascular Medicine
Spotlight on HDL-raising Therapies: Insights From the Torcetrapib Trials CME

Disclosures

Release Date: April 28, 2008; Valid for credit through April 28, 2009
Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians

Contents of This CME Activity
    To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

  1. Spotlight on HDL-raising Therapies: Insights From the Torcetrapib Trials
    Anatol Kontush, BSc, PhD
    Maryse Guérin, PhD
    M. John Chapman, BSc (Hons), PhD, DSc

Go to Test Questions

 
Legal Disclaimer
The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Copyright © 2008 Medscape.

 
Medscape
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Describe the physiology of high-density lipoprotein (HDL) and treatments targeting HDL
  2. Identify the primary safety concern of torcetrapib
  3. Specify outcomes associated with torcetrapib therapy
  4. Identify the potential efficacy and safety of anacetrapib
Authors and Disclosures

Anatol Kontush, BSc, PhD
Disclosure: Anatol Kontush, BSc, PhD, has disclosed that he has served as a consultant to, is on the speakers' bureau for, and has received grant or research support from Pfizer.


Maryse Guérin, PhD
Disclosure: Maryse Guérin, PhD, has disclosed that she has received grant or research support from Pfizer.


M. John Chapman, BSc (Hons), PhD, DSc
Disclosure: M. John Chapman, BSc (Hons), PhD, DSc, has disclosed that he has served as a consultant to, is on the speakers' bureau for, and has received grant or research support from Pfizer.


Charles P. Vega, MD
Disclosure: Charles P. Vega, MD, has disclosed that he has served as an advisor or consultant to Novartis, Inc.


Hannah Camm
Disclosure: Hannah Camm has disclosed no relevant financial relationships.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.